Sphera Funds Management LTD. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Sphera Funds Management LTD. bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 68,333 shares of the company’s stock, valued at approximately $3,659,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares during the period. Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after acquiring an additional 599 shares during the period. Kennedy Capital Management LLC increased its position in Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after purchasing an additional 928 shares during the period. MetLife Investment Management LLC increased its position in Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock worth $926,000 after purchasing an additional 949 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after purchasing an additional 1,095 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JANX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush reissued an “outperform” rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Scotiabank decreased their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $95.25.

Janux Therapeutics Stock Performance

JANX stock opened at $23.27 on Friday. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71. The stock’s 50 day moving average price is $28.76 and its 200 day moving average price is $40.94. The firm has a market cap of $1.38 billion, a P/E ratio of -19.89 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.